Articles
| Open Access |
DOI: Determination Of Risk Parameters In The Detection Of Asymptomatic Bone Metastases Of Kidney And Prostate Cancer
Shakhanova Sh.Sh. , Samarkand Medical Institute, Uzbekistan Djuraev M.D. , Samarkand Medical Institute, Uzbekistan Rakhimov N.M. , Samarkand Medical Institute, Uzbekistan Karimova M.N. , Samarkand Medical Institute, Uzbekistan Asatulayev A.F. , Samarkand Medical Institute, UzbekistanAbstract
Using multivariate analysis to identify predictive risk parameters in the diagnosis of asymptomatic osteogenic metastasis of renal and prostate cancer. The work was based on the results of observations of 105 patients with a morphologically confirmed diagnosis of malignant neoplasm registered at the Republican Specialized Scientific and Practical Center of Oncology and Radiology (RSNPMTSO and R) and the Samarkand branch. In 62 patients with kidney cancer (RP) included in the study, the mean age of patients with RP was 58.3 years. 43 patients with prostate cancer (PC) were included in the study, the average age of patients with PC was 68 years. We analyzed such parameters as age, stage of the disease, timing of detection of bone metastasis (BM), prevalence, type and size of BM, as well as additional criteria: in case of prostate cancer - the size of the primary tumor and the degree of malignancy, in case of prostate cancer - the sum of points on the Gleason scale and the prostate -specific antigen (PSA). It was revealed that the highest risk in detecting BM in RP was noted for the stage of the disease, p = 0.006. Also, a high risk was associated with the size and grade of tumor malignancy, with CR at p = 0.006 and p = 0.008, respectively. Among the listed, the highest risk in detecting BM is observed in prostate cancer for the stage of the disease (p = 0.001). In addition, an increased risk was observed for the Gleason score and PSA level (p = 0.013 and p = 0.008, respectively). Thus, during the 2-year follow-up, BM most often develops in patients with kidney cancer at stage Tv-T3a stage and with grade G III and in patients with prostate cancer - in the presence of stage III with a Gleason score of ≥ 7 and a level PSA in the range of 21-50 ng / ml.
Keywords
Patients, vessels, treatment, pathology, cancer, distant bone metastases
References
Lipton, A. The Science and Practice of Bone Health in Oncology: Managing Bone Loss and Metastasis in Patients With Solid Tumors / A. Lipton // J. Nat. Compr. Canc. Netw. - 2009. - Vol. 7. - P. 1-29
Tillyashaikhov MN, Yusupov Sh. Kh., Boyko EV, Valieva RM Criteria for choosing hormonal therapy for patients with advanced prostate cancer // Bulletin of the Tashkent Medical Academy. - 2016. - No. 2 (05). - S. 95–97
Tillyashaikhov MN, Rakhimov NM, Tillyashaikhova RM Evolution of views on the diagnosis and treatment of renal cell cancer // Medical Journal of Uzbekistan. - Tashkent, 2018.- №4. - S. 51-55.
Tillyashayakhov M. N., Rahimov N. M., Tillyashayakhova R. M. Long-term results of modified surgical access to regional lymph nodes and main vessels in the treatment of renal cell carcinoma // European science review. - Vienna, 2018.-No. 5-6. -R. 204-207
Rahimov N, Shakhanova Sh. Development of new approaches in treatment of metastatic renal cell carcinoma // Journal of research in health science Volume 5-6 issue. 4 2020, pp. 82-95 ISSN 2523-1251 (Online)), p 82-95.
Saidkulov B, Abduraxmonov A, Rahimov N. Recurrent ovarian cancer: mechanisms of development of peritoneal malignant ascites //. European Journal of Molecular & Clinical Medicine ISSN 2515-8260 Volume 7, Issue 2, 2020, p 2423-2428
Ziyadullaev Sh, Elmamatov O, F Raufov Cytogenetic and immunological alterations of recurrent bladder cancer // European Journal of Molecular & Clinical Medicine 2020, Volume 7, Issue 2, p 1877-1883.
Santoni M., Conti A., Procopio G., Porta C., Ibrahim T., Barni S. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? J. Exp. Clin. Canc. Res. 2015; 34 (1): 1
Masood Umer, Yasir Mohib, * Muhammed Atif, and Muhammad Nazim Skeletal metastasis in renal cell carcinoma: A review Ann Med Surg (Lond). 2018 Mar; 27: 9–16.Published online 2018 Jan 31. doi: 10.1016 / j.amsu.2018.01.002.
Bollen, L., Jacobs, W.C.H., Van der Linden, Y.M. et al. A systematic review of prognostic factors predicting survival in patients with spinal bone metastases. Eur Spine J 27, 799-805 (2018). https://doi.org/10.1007/s00586-017-5320-3
Crawford, E.D., et al., Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology, 2014.83 (3): p. 664-9.
F Ruatta, L Derosa, B Escudier, E Colomba, A Guida, G Baciarello, Y Loriot, K Fizazi, L Albiges, European Journal of Cancer. Prognosis of Renal Cell Carcinoma With Bone Metastases: Experience From a Large Cancer Center Eur. J. Cancer 2018 Dec 11; 107 (xx) 79-85
Article Statistics
Copyright License
Copyright (c) 2021 The American Journal of Medical Sciences and Pharmaceutical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.